RU2331425C2 - Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов - Google Patents

Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов Download PDF

Info

Publication number
RU2331425C2
RU2331425C2 RU2006107652/15A RU2006107652A RU2331425C2 RU 2331425 C2 RU2331425 C2 RU 2331425C2 RU 2006107652/15 A RU2006107652/15 A RU 2006107652/15A RU 2006107652 A RU2006107652 A RU 2006107652A RU 2331425 C2 RU2331425 C2 RU 2331425C2
Authority
RU
Russia
Prior art keywords
day
composition according
estrogen receptor
estrogen
mcg
Prior art date
Application number
RU2006107652/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2006107652A (ru
Inventor
Эндрю Джордж ЛИ (US)
Эндрю Джордж ЛИ
Original Assignee
Висконсин Эламнай Рисерч Фаундейшн (ВАРФ)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Висконсин Эламнай Рисерч Фаундейшн (ВАРФ) filed Critical Висконсин Эламнай Рисерч Фаундейшн (ВАРФ)
Publication of RU2006107652A publication Critical patent/RU2006107652A/ru
Application granted granted Critical
Publication of RU2331425C2 publication Critical patent/RU2331425C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2006107652/15A 2003-09-19 2004-09-06 Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов RU2331425C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452103P 2003-09-19 2003-09-19
US60/504,521 2003-09-19

Publications (2)

Publication Number Publication Date
RU2006107652A RU2006107652A (ru) 2007-10-27
RU2331425C2 true RU2331425C2 (ru) 2008-08-20

Family

ID=34375516

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006107652/15A RU2331425C2 (ru) 2003-09-19 2004-09-06 Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов

Country Status (16)

Country Link
US (1) US20050070512A1 (enExample)
EP (1) EP1667692A1 (enExample)
JP (1) JP2007505881A (enExample)
KR (1) KR20060040746A (enExample)
CN (1) CN100496501C (enExample)
AU (1) AU2004273658A1 (enExample)
BR (1) BRPI0414448A (enExample)
CA (1) CA2539361A1 (enExample)
CO (1) CO5670328A2 (enExample)
IL (1) IL173621A0 (enExample)
MX (1) MXPA06003122A (enExample)
NO (1) NO20061702L (enExample)
RU (1) RU2331425C2 (enExample)
TW (1) TW200522967A (enExample)
WO (1) WO2005027924A1 (enExample)
ZA (1) ZA200601237B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
WO2005051323A2 (en) 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
CA2597624C (en) * 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7511030B2 (en) * 2005-02-11 2009-03-31 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2
WO2006105221A1 (en) * 2005-03-29 2006-10-05 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(23S)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE AND 2-METHYLENE-19-NOR-(23R)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US20090036429A1 (en) * 2006-02-17 2009-02-05 Ohler Norman E Hydroxypiperidine Derivatives and Uses Thereof
EP2141994A4 (en) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals POLYCYCLIC COMPOUNDS AND USES THEREOF
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
RU2107512C1 (ru) * 1991-06-05 1998-03-27 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO2002091993A3 (en) * 2001-05-10 2003-03-20 Merck & Co Inc Estrogen receptor modulators

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) * 1962-09-13
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
EP0260066B1 (en) * 1986-09-11 1990-05-09 National Research Development Corporation Tamoxifen derivatives
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
AUPO727097A0 (en) * 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
EP1301189A2 (en) * 2000-07-14 2003-04-16 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D 3? TO INCREASE BONE STRENGTH
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2107512C1 (ru) * 1991-06-05 1998-03-27 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция для остеоиндукции, способ генерации новой кости
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
WO2002091993A3 (en) * 2001-05-10 2003-03-20 Merck & Co Inc Estrogen receptor modulators

Also Published As

Publication number Publication date
CO5670328A2 (es) 2006-08-31
RU2006107652A (ru) 2007-10-27
MXPA06003122A (es) 2006-05-31
KR20060040746A (ko) 2006-05-10
CN1852720A (zh) 2006-10-25
IL173621A0 (en) 2006-07-05
AU2004273658A1 (en) 2005-03-31
EP1667692A1 (en) 2006-06-14
TW200522967A (en) 2005-07-16
NO20061702L (no) 2006-06-19
CA2539361A1 (en) 2005-03-31
US20050070512A1 (en) 2005-03-31
BRPI0414448A (pt) 2006-11-14
CN100496501C (zh) 2009-06-10
WO2005027924A1 (en) 2005-03-31
ZA200601237B (en) 2007-05-30
JP2007505881A (ja) 2007-03-15

Similar Documents

Publication Publication Date Title
RU2331425C2 (ru) Фармацевтические композиции и способы, включающие комбинации производных 2-алкилиден-19-нор-витамина d и агониста/антагониста эстрогенов
EP0462189B1 (en) Combination therapy for treatment of estrogen sensitive diseases
US7030157B2 (en) Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
EP2036902A3 (en) Urea compounds active as vanilloid receptor antagonist for the treatment of pain
CA2360313A1 (en) Glucocorticoid receptor modulators
RU2003107921A (ru) Селективные циклопептиды
CA2360308A1 (en) Glucocorticoid receptor modulators
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
BG106142A (en) Glucocorticoid receptor modulators
RU95112537A (ru) Терапевтические гетероциклические соединения, способ их получения, фармацевтическая композиция, способ ее получения
PT2223688T (pt) (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilaminoisoindolino-1,3-diona: métodos de utilização e composições do mesmo
GEP20105025B (en) Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
EP1741712A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of Nebivolol
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
JP2019524797A5 (enExample)
WO2005118579A3 (en) Thiazole derivatives as chemokine receptor antagonists
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
WO2004093789A3 (en) Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
NO20060191L (no) 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)2,2-difenylacetamidderivater som muskarinreceptoragonister
PL1660484T3 (pl) Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
TW200517127A (en) Novel composition
WO1997046252A1 (en) Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
BR0011094A (pt) Polimorfos de um citrato cristalino de azobiciclo[2,2,2]octan-3-amina e suas composições farmacêuticas

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090907